Approval of remdesivir recommended for treatment of coronavirus

The Scientific Committee for Human Medicinal Products, which operates within the European Medicines Agency (EMA), has recommended to this agency the conditional approval of the drug remdesivir to treat the disease COVID-19. This is the first drug to be recommended for approval at the EMA and the decision, according to the communication of this institution, is expected to be taken within a few days.

the product, according to the release, is recommended for the treatment of adults and children over 12 years old infected with COVID-19, who have pneumonia and need additional oxygen. These are some of the conditions given by the Medical Committee for the use of this drug and the categories of patients who should use this drug.

According to the EMA statement, overall, the study showed that patients treated with remdesivir recovered after about 11 days, compared to 15 days for patients receiving placebo (placebo is used as a term for a drug with no healing effect that given to patients to convince them they are getting the real treatment).

"This effect was not seen in patients with mild to moderate disease, where recovery time was 5 days for both the remdesivir and placebo groups. For patients with severe disease, who made up approximately 90 percent of patients in the study, recovery time was 12 days in the remdesivir group and 18 days in the placebo group," the EMA statement said.

After the recommendation for the approval of this drug, the president of the Chamber of Pharmacists of Kosovo, Arianit Jakupi, said that it is important that Kosovo can provide a quantity of doses that could be used in patients who are in a serious condition for avoid fatality.